Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

10-year Treasury yield rises back to 5% as global tightening wave pushes

US Treasury yields rise on Friday, boosted mainly by the Federal Reserve’s (Fed) decision to increase rates on Wednesday, while the Bank of Japan (BoJ) added its name to the list of major central banks focused on preventing inflation from getting out of control.

10-year Treasury yield rises back to 5% as global tightening wave pushes

On Friday, US Treasury yields surged back to 5%, reaching their highest level since 2007. The Federal Reserve's decision to raise interest rates on Wednesday played a significant role in this increase. The Bank of Japan also joined the trend, raising its interest rates for the first time in 31 years, marking a 25 basis point increase.

This wave of global tightening by major central banks aimed to curb inflation from escalating. The Middle East conflict uncertainty further drove oil prices up, adding to inflation risks. As a result, the Fed and BoJ raised rates to make borrowing more expensive and to discourage spending, which could help control inflation. This move made US bonds less attractive, pushing their yields higher.

The Fed's decision was a clear signal that they foresee more rate hikes in the future, with market expectations now at 34 basis points of tightening by the end of 2026. The odds of a rate hike in October stood at 55%, while in December, the probability rose to 90%. Despite the US economy showing a flat industrial production growth in August, investors are closely watching upcoming economic data, including speeches from Fed officials, jobs reports, and S&P Flash PMIs.

Written by urgent.news from FXStreet's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 3 other outlets

Read the original at fxstreet.com →

More in Finance & Markets

Why XRP Is Up Today

XRP rose on Friday as oil prices eased and the SEC offered limited relief for tokenized-stock trading.

Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases…

  • Axsome Therapeutics focuses on CNS conditions with AUVELITY, SUNOSI, and SYMBRAVO
  • Moderna leverages mRNA technology for broad therapeutic applications beyond COVID-19
  • Both companies operate in high-risk, high-reward biopharmaceutical environment

More from Friday 18 September →